Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Influenza A H5 hemagglutinin (HA) protein is a surface glycoprotein essential for the infectivity and host specificity of influenza viruses, particularly those of the H5 subtype. It mediates viral attachment to host cells via sialic acid binding and triggers membrane fusion, enabling viral entry. It is a major target for neutralizing antibodies, but is subject to antigenic drift, which poses challenges for vaccine development. The amino acid sequence at the HA1/HA2 cleavage site influences pathogenicity.
Neutralizing antibodies bind to hemagglutinin, blocking receptor binding and/or membrane fusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus hemagglutinin protein subtype H5 (H5 HA).